Remarks

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Claims 58-74 have been cancelled without prejudice or disclaimer thereto. Claim 75 is pending. Further, claim 76 is newly added. Support can be found on page 23, line 4 of the specification as filed.

No new matter has been added.

On page 2, claim 58 was objected to. Further, on pages 2-4, claim 63 was rejected under 35 U.S.C. §112.

These rejections are most as the noted claims have been cancelled without prejudice or disclaimer thereof.

On pages 5-6, claims 58-65, 68-71 and 75 were rejected under 35 U.S.C. §102(e) as anticipated by Fang et al. Further, on pages 7-8, claims 58-75 were rejected under 35 U.S.C. §103(a) as obvious over Fang et al. in view of Heinrikson et al., Sgarlato and Huston et al.

Applicants respectfully traverse these rejections as applied to the remaining claim.

Initially, it is noted that the Office Action fails to establish a *prima facie* case of obviousness or anticipation regarding claim 75. In particular, claim 75 is directed toward a vertebrate host cell having Golgi-only or late-Golgi-only resident subtilisin/kexin family endoprotease activity but the Office Action fails to establish that this reference teaches or suggests such. Further, it is noted that pages 22-23 of the specification teach advantages of such cells. For instance, such endoproteases generally do not require strongly basic cleavage site motifs. Thus, carboxypeptidase trimming is not needed after cleavage.

Thus, these rejections as applied to claim 75 as well as new claim 76 are untenable and should be withdrawn.

In view of the foregoing amendments and remarks, the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Robert KALLMEIER et al.

/William R. Schmidt, II/

Digitally signed by /William R. Schmidt, II/ DN: cn=/William R. Schmidt, II/, o=WLP, ou, email=bschmidt@wenderoth.com, c=US

Date: 2009.07.23 14:16:57 -04'00'

By:

William R. Schmidt, II Registration No. 58,327 Attorney for Applicants

WRS/pth Washington, D.C. 20005-1503 Telephone (202) 721-8200 Facsimile (202) 721-8250 July 23, 2009